Effects of different hypoglycaemic drugs on beta-cell function in type 2 diabetes mellitus: a systematic review and network meta-analysis.

Guo Z, Huang L, Jiang Z, Bai X, Wang Z, Huang H

European journal of medical research21 Feb 2025Cited by 3 (Europe PMC)

PMID39985051PMCIDPMC11843998DOI10.1186/s40001-025-02368-yPepBankPUB-39985051

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

01HumanSystematic reviewEfficacy outcome
In reviewed T2D patients, liraglutide had HbA1c-change WMD -1.77 (95% CI -2.33 to -1.21); the original estimate reference and units were unstated.
In plain wordsIn reviewed T2D patients, liraglutide showed an HbA1c-reduction estimate; the original comparison was unspecified.
Peptide
Liraglutide
Outcome
DecreaseHbA1c
Study
n: not reported in source
Analysis
Secondary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Measurements
WMD
−1.77
liraglutide
95% CI
−2.33 to −1.21
liraglutide
Source sentences
Summary
and liraglutide (WMD = - 1.77, 95% CI - 2.33 to - 1.21).
3 context sentences(design, population, supporting numbers)
Summary · context
This study compared the effects of hypoglycaemic drugs on beta-cell function among type 2 diabetes mellitus (T2DM) patients through a network meta-analysis of randomized controlled trials (RCTs).
Summary · context
We searched the PubMed, EMBASE, and Cochrane Library databases for RCTs of different hypoglycaemic drugs as T2DM treatment from database inception to December 1, 2024.
Summary · context
The primary outcome was homeostasis model assessment-β (HOMA-β), and the secondary outcome was glycated haemoglobin (HbA1c).
Report a problemFND-3998505101
02HumanSystematic reviewEfficacy outcome
In reviewed T2D patients, liraglutide was listed alongside metformin plus exenatide among treatments following glibenclamide plus rosiglitazone in HbA1c-lowering efficacy; no direct ranking-difference coefficient was reported.
In plain wordsIn reviewed T2D patients, liraglutide was listed among treatments following glibenclamide/rosiglitazone in HbA1c-lowering efficacy; no direct-comparison estimate was reported.
Peptide
Liraglutide
Outcome
Not applicableHbA1c-lowering treatment ordering
Study
n: not reported in source
Comparator
Glibenclamide plus rosiglitazone
Analysis
Secondary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
For reducing HbA1c, glibenclamide + rosiglitazone was the most efficacious treatment (WMD = - 2.48, 95% CI - 3.67 to - 1.29), followed by metformin + exenatide (WMD = - 1.77, 95% CI - 2.25 to - 1.29) and liraglutide (WMD = - 1.77, 95% CI - 2.33 to - 1.21).
2 context sentences(design, population, supporting numbers)
Summary · context
We searched the PubMed, EMBASE, and Cochrane Library databases for RCTs of different hypoglycaemic drugs as T2DM treatment from database inception to December 1, 2024.
Summary · context
The primary outcome was homeostasis model assessment-β (HOMA-β), and the secondary outcome was glycated haemoglobin (HbA1c).
Report a problemFND-3998505102

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.